Compare Illumina, Inc. (ILMN) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs SiTime Corporation — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while SiTime Corporation trades at $684.4 (market cap $20.73B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| ILMN | SITM | |
|---|---|---|
Market Cap | $28.96B | $20.73B |
Sector | Health | Technology |
52-Week High | $205.10 | $901.60 |
52-Week Low | $91.00 | $212.77 |
Enterprise Value | $30.32B | $20.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
SITM stock surged 5.5% to $725.28, showing strong momentum with three consecutive quarterly earnings beats and bullish technical indicators. The company reported 127% revenue growth in Q2 2026 and expects further acceleration from AI infrastructure demand and the Renesas acquisition. Despite negative 2025 earnings, profitability improved significantly with net income turning positive in 2026 projections.
Outlook remains positive with 100% analyst buy ratings and $870 consensus target, though premium valuations (P/E 1,148, P/S 39) and execution risks from the Renesas integration warrant caution. AI timing growth presents substantial opportunity, but stock appears fully valued after recent run-up.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
